140 related articles for article (PubMed ID: 18704303)
41. Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.
Le Mire MF; Miller DS; Foster WK; Burrell CJ; Jilbert AR
J Virol; 2005 Oct; 79(19):12242-52. PubMed ID: 16160150
[TBL] [Abstract][Full Text] [Related]
42. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Pekin ducks infected with the viruses.
Tomita T; Yokosuka O; Tagawa M; Saisho H; Tamura S; Fukuda I; Omata M
J Hepatol; 2000 May; 32(5):850-8. PubMed ID: 10845674
[TBL] [Abstract][Full Text] [Related]
43. Characterisation of the Indian strain of duck hepatitis B virus (DHBV) and development of a carrier duck colony for antiviral drug testing.
Munshi A; Mehrotra R; Panda SK
Trop Gastroenterol; 1994; 15(2):77-85. PubMed ID: 7831721
[TBL] [Abstract][Full Text] [Related]
44. In vivo antiviral effects of mismatched double-stranded RNA on duck hepatitis B virus.
Ijichi K; Mitamura K; Ida S; Machida H; Shimada K
J Med Virol; 1994 Jun; 43(2):161-5. PubMed ID: 8083664
[TBL] [Abstract][Full Text] [Related]
45. Antisense therapy of hepatitis B virus infection.
Offensperger WB; Offensperger S; Blum HE
Mol Biotechnol; 1998 Apr; 9(2):161-70. PubMed ID: 9658393
[TBL] [Abstract][Full Text] [Related]
46. Anti-HBV effect of individual traditional Chinese herbal medicine in vitro and in vivo: an analytic review.
Chen Y; Zhu J
J Viral Hepat; 2013 Jul; 20(7):445-52. PubMed ID: 23730837
[TBL] [Abstract][Full Text] [Related]
47. 2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.
Zoulim F; Dannaoui E; Borel C; Hantz O; Lin TS; Liu SH; Trépo C; Cheng YC
Antimicrob Agents Chemother; 1996 Feb; 40(2):448-53. PubMed ID: 8834896
[TBL] [Abstract][Full Text] [Related]
48. Protocatechuic aldehyde inhibits hepatitis B virus replication both in vitro and in vivo.
Zhou Z; Zhang Y; Ding XR; Chen SH; Yang J; Wang XJ; Jia GL; Chen HS; Bo XC; Wang SQ
Antiviral Res; 2007 Apr; 74(1):59-64. PubMed ID: 17298850
[TBL] [Abstract][Full Text] [Related]
49. Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.
Le Guerhier F; Pichoud C; Guerret S; Chevallier M; Jamard C; Hantz O; Li XY; Chen SH; King I; Trépo C; Cheng YC; Zoulim F
Antimicrob Agents Chemother; 2000 Jan; 44(1):111-22. PubMed ID: 10602731
[TBL] [Abstract][Full Text] [Related]
50. Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model.
Bishop N; Civitico G; Wang YY; Guo KJ; Birch C; Gust I; Locarnini S
J Med Virol; 1990 Jun; 31(2):82-9. PubMed ID: 2388048
[TBL] [Abstract][Full Text] [Related]
51. Reduced duck hepatitis B virus viraemia in ducklings coinfected with the immunodepressive reticuloendotheliosis virus.
Dixon RJ; Jones NF; Freiman JS
J Med Virol; 1990 Mar; 30(3):169-73. PubMed ID: 2160513
[TBL] [Abstract][Full Text] [Related]
52. Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo.
Li CQ; Zhu YT; Zhang FX; Fu LC; Li XH; Cheng Y; Li XY
World J Gastroenterol; 2005 Jan; 11(3):426-8. PubMed ID: 15637760
[TBL] [Abstract][Full Text] [Related]
53. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro.
Wang GF; Shi LP; Ren YD; Liu QF; Liu HF; Zhang RJ; Li Z; Zhu FH; He PL; Tang W; Tao PZ; Li C; Zhao WM; Zuo JP
Antiviral Res; 2009 Aug; 83(2):186-90. PubMed ID: 19463857
[TBL] [Abstract][Full Text] [Related]
54. Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks.
Fourel I; Li J; Hantz O; Jacquet C; Fox JJ; Trépo C
J Med Virol; 1992 Jun; 37(2):122-6. PubMed ID: 1629711
[TBL] [Abstract][Full Text] [Related]
55. Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.
Quinet J; Jamard C; Burtin M; Lemasson M; Guerret S; Sureau C; Vaillant A; Cova L
Hepatology; 2018 Jun; 67(6):2127-2140. PubMed ID: 29251788
[TBL] [Abstract][Full Text] [Related]
56. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks.
Fourel I; Cullen JM; Saputelli J; Aldrich CE; Schaffer P; Averett DR; Pugh J; Mason WS
J Virol; 1994 Dec; 68(12):8321-30. PubMed ID: 7966625
[TBL] [Abstract][Full Text] [Related]
57. [Anti-virus effect of combination of attenuated measles virus with 3TC on duck hepatitis B model].
Yang Z; Deng X; Zhang F
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Mar; 15(1):39-42. PubMed ID: 12526301
[TBL] [Abstract][Full Text] [Related]
58. In vivo and in vitro anti-hepatitis B virus activity of total phenolics from Oenanthe javanica.
Han YQ; Huang ZM; Yang XB; Liu HZ; Wu GX
J Ethnopharmacol; 2008 Jun; 118(1):148-53. PubMed ID: 18495393
[TBL] [Abstract][Full Text] [Related]
59. [A study of duck hepatitis B virus infection in Chinese ducklings].
Leng J; Xu BD
Zhonghua Bing Li Xue Za Zhi; 1992 Jun; 21(3):160-3. PubMed ID: 1477940
[TBL] [Abstract][Full Text] [Related]
60. Antiviral activities of penciclovir and famciclovir on duck hepatitis B virus in vitro and in vivo.
Offensperger WB; Offensperger S; Keppler-Hafkemeyer A; Hafkemeyer P; Blum HE
Antivir Ther; 1996 Aug; 1(3):141-6. PubMed ID: 11322247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
